Petr Jarolim's bio:

Petr Jarolim, MD, PhD, is Medical Director of Clinical Chemistry and Laboratory Control at Brigham and Women's Hospital (BWH) and Dana Farber Cancer Institute (DFCI), Medical Director of Clinical Laboratories at the Ambulatory Care Center and the Lown Cardiovascular Center. He also directs the Biomarker Research /TIMI Clinical Trials Laboratory in the Department of Pathology at Brigham and Women’s Hospital. He is Associate Professor of Pathology at Harvard Medical School where he has been since 1994. He currently supervises selection and implementation of analyzers and total lab automation at BWH and DFCI. He is the Principal Investigator in multiple trials of both established and novel cardiovascular and tumor biomarkers.

Prior to joining Brigham and Women’s Hospital, Dr. Jarolim worked at Tufts University Medical School in Boston, where he was involved in research on molecular genetics of hereditary hemolytic anemias and blood group antigens. He described mutations in the red cell membrane proteins that cause various types of anemia and underlie malaria resistance and his laboratory discovered molecular basis of multiple blood group antigens. Dr. Jarolim has published more than 80 original articles in cardiology, hematology, transfusion medicine and chemistry journals and has authored and co-authored multiple reviews and book chapters.

Dr. Jarolim works on the Expert Review Panel of the American Society of Clinical Pathology and serves on committees of the Academy of Clinical Laboratory Physicians and Scientists. Prior to coming to Boston in 1990, Dr. Jarolim worked in Prague, Czech Republic, where he briefly practiced hematology and studied biophysical properties of cell membranes. Between 1996 and 2002, while working at the Brigham and Women’s Hospital, he directed the Institute of Hematology and Blood Transfusion in Prague.

Dr. Jarorim has disclosed that he has research support from Siemens Healthcare Diagnostics, Ortho Clinical Diagnostics, Roche Diagnostics, Beckman Coulter, and Amgen. He serves on the Scientific Advisory Board for Roche Diagnostics and receives honorarium as a consultant from T2 Biosystems and Gerson-Lehrman.